Marinomed Biotech Ag · VIE:MARI

Marinomed Biotech — FY2018 Earnings Presentation

11 slides from Marinomed Biotech's earnings presentation, Apr 30, 2019

  1. Slide 1: Results for Full Year 2018 Investors Update Presentation

    Creating innovative therapies for allergy, respiratory and eye diseases Results for Full Year 2018 Investors Update Presentation Vienna, 30 April 2019

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy

  3. Slide 3: Set the basis in 2018…

    Set the basis in 2018… Marinomed achieved major milestones in 2018 Corporate  Established a high profile  Budesolv evolved into a  New partnerships in CA, TR, Scientific Advisory Board: phase III asset, European SK, UA, MD, BY, GE, AM, UZ, Ron Eccles (Mr. Cold, UK), Bala market authorization path

  4. Slide 4: …continued with delivery in 2019

    …continued with delivery in 2019 Strong start into 2019 allows for accelerated development going forward Phase III €22.4m >30 Top-line results for Financing raised in countries launched Budesolv Feb 1, 2019 IPO >$12bn1 $28bn2 market for 1st market for product based on 6+3 €15.0m 6 products on the Ve

  5. Slide 5: Marinosolv with significant milestones

    Marinosolv® with significant milestones Progress as promised with future untapped potential Positive Top-line results Market approval process on track  Budesolv achieves major milestone  Approval process can be continued as planned  Budesolv achieves at least the same effect as  H2/2019 – genera

  6. Slide 6: Carragelose products continue expansion

    Carragelose® products continue expansion Coldamaris lozenges Coldamaris throatspray Coldamaris lozenges Coldamaris akut Coldamaris throatspray Coldamaris akut Multiple additional launches and line extensions planned in the coming years Regulatory status Regulatory Medical device status Medical Is de

  7. Slide 7: Statement of profit or loss (IFRS)

    Statement of profit or loss (IFRS) €m 2018 2017 1 Revenue €m 2018 2017 Revenues 1 4.7 4.8 Sale of goods 4.4 4.6 Other income 0.7 0.8 License revenues 0.1 0.1 Other net gains/losses 0.0 0.0 Other revenues 0.1 0.1 Materials and services expenses 2 (4.8) (4.2) Total revenue 4.7 4.8 Personnel expenses (

  8. Slide 8: Statement of financial position (IFRS)

    Statement of financial position (IFRS) €m 2018 2017 €m 2018 2017 Assets Equity and liabilities Intangible assets 1.3 1.3 Share capital 1.0 0.1 Property, plant and equipment 0.2 0.2 Capital reserves 7.0 7.0 Deposits and other non-current Retained losses (24.2) (12.1) 0.0 0.0 receivables Total capital

  9. Slide 9: Statement of cash flows (IFRS)

    Statement of cash flows (IFRS) 9

  10. Slide 10: Positive outlook for 2019

    Positive outlook for 2019 Investments in Marinosolv® and commercialization of Carragelose® Indicative timetable We remain optimistic for 2019 with positive developments  Continued expansion of the distribution collaborations and planned new launches  Renewed revenue growth and positive development

  11. Slide 11: www.marinomed.com

    : Orrarino www.marinomed.com

Marinomed Biotech — FY2018 Earnings Presentation on 6ix